NGENF NERVGEN PHARMA CORP
- 1.550
- +0.020+1.31%
- 1.537
- -0.013-0.86%
NERVGEN PHARMA CORP News
NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus
NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus
NervGen Pharma GAAP EPS of -$0.38
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update
NervGen Pharma Corp. (NGEN.V), a biotech company developing solutions to treat nervous system damage, reported a net loss of $22.4 million, or $(0.38) per basic and diluted share for the year ended De
NervGen Completes $23 Million Bought Deal Financing
NervGen Pharma GAAP EPS of -$0.07
NervGen Pharma GAAP EPS of -$0.08
NervGen Pharma Appoints Michael Kelly as President & CEO
NervGen Pharma GAAP EPS of -$0.39
NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 42% Below Their Intrinsic Value Estimate
NervGen Grants 400K Stock Options to Directors
NervGen Pharma Reports Q3 Results
NervGen Pharma Appoints Bill Radvak as Interim CEO
NervGen Pharma (OTCQX:NGENF) notifies that the board and Paul Brennan have mutually agreed that Mr. Brennan will step down as President & CEO and a member of the board, effective immediately. The
NervGen Pharma GAAP EPS of -$0.13
NervGen Pharma press release (OTCQX:NGENF): Q2 GAAP EPS of -$0.13. Cash position enhanced by over $22M.
NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - June 30, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF)
NervGen Pharma GAAP EPS of -$0.11
NervGen Pharma press release (OTCQX:NGENF): Q1 GAAP EPS of -$0.11.NervGen had cash and investments of $12.8 million as of March 31, 2022, compared to $5.0 million as of March 31, 2021. The net cash
NervGen Pharma gets safety panel nod to advance in phase 1 trial of NVG-291
NervGen Pharma (OTCQX:NGENF) received approval from A safety review committee to advance to the second cohort in the multiple ascending dose (MAD) portion of its phase 1 trial of NVG-291. The company
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation
Phase 1b/2a trial of NervGen's lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal studies demonstrating pronounced functional recovery from spinal cord injury "The ability of NVG-291 to demonstrate meaningful recovery in
The number of fraud cases doubled during the blockade of the epidemic in the UK.
The number of fraud cases in the UK has soared this year as the COVID-19 epidemic has created perfect conditions for criminals to use the blockade to carry out fraud. Fraud charges in British courts doubled in the first six months of this year, according to a report released by KPMG UK on Wednesday. However, despite the surge in the number of cases, the amount involved fell by 70 per cent to £139 million (about $193 million), a fraction of the £895 million in the first half of 2018. Roy Vallegora (Roy Waligora), KPMG's head of UK investigation, said the drop in the value of the case may be due to a lack of
Industrial Alliance Initiates Coverage On NervGen Pharma with Speculative Buy Rating, Announces Price Target of $6
Industrial Alliance initiates coverage on NervGen Pharma (OTC:NGENF) with a Speculative Buy rating and announces Price Target of $6.
NervGen Pharma analyst ratings
DateResearch FirmActionCurrentPT 7/13/21Industrial AllianceInitiates Coverage OnSpeculative Buy6.0
Analysis
Price Target
No Data
